New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePT-141 (Bremelanotide) vs Follistatin

PT-141 (Bremelanotide) vs Follistatin

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Anabolic & IGF
Follistatin
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
Half-Life
2–3 hours
~3–5 hours (endogenous form)
Admin Route
SubQ
IM, SubQ
Research
Typical Dose
0.5–1.75 mg
50–100 mcg per injection site
Frequency
As needed (not daily)
Every other day or 2–3x per week
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Potent myostatin inhibition enabling supraphysiological muscle growth
  • Increases skeletal muscle mass and fiber size
  • May accelerate recovery from muscle injury
  • Potential benefits in muscular dystrophy and sarcopenia
  • Synergistic with IGF-1 and growth hormone in anabolic protocols
  • Animal studies show dramatic increases in muscle mass
  • Reduces muscle fibrosis in dystrophic models
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Potential for excessive muscle growth if doses are not controlled
  • FSH suppression with implications for fertility in women
  • Theoretical risk of cardiac hypertrophy with prolonged high-dose use
  • Limited human safety data available
  • +1 more
Stacks With